Literature DB >> 22931583

Guillain-Barré syndrome following adalimumab treatment.

Stefania Manganelli, Marco Rossi, Marco Tuccori, Mauro Galeazzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22931583

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN： 0392-856X            Impact factor:   4.473


× No keyword cloud information.
  3 in total

1.  Non-length-dependent and length-dependent small-fiber neuropathies associated with tumor necrosis factor (TNF)-inhibitor therapy in patients with rheumatoid arthritis: expanding the spectrum of neurological disease associated with TNF-inhibitors.

Authors:  Julius Birnbaum; Clifton O Bingham
Journal:  Semin Arthritis Rheum       Date:  2013-10-30       Impact factor: 5.532

Review 2.  Severe Guillain-Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review.

Authors:  Bonifacio Alvarez-Lario; Rosa Prieto-Tejedo; María Colazo-Burlato; Jesús Macarrón-Vicente
Journal:  Clin Rheumatol       Date:  2013-05-11       Impact factor: 2.980

3.  Guillain-Barré syndrome in a patient on adalimumab for the treatment of psoriasis.

Authors:  Natallia Barreiros de Natividade; Paulo Antonio Oldani Felix; Claudio Lerer
Journal:  An Bras Dermatol       Date:  2017       Impact factor: 1.896
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.